Skip to main content
SpringerLink
Log in

Kein vorteil durch zusätzliche CMF-Behandlung bei nodal positivem, postmenopausalem, Rezeptor-positivem Mammakarzinom unter adjuvanter Tamoxifen-Therapie

  • Literatur Kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Castiglione-Gertsch M, Johnsen C, Goldhirsch A et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994;5:717–24.

    PubMed  CAS  Google Scholar 

  2. Cavalli F, Beer M, Martz G et al. Gleichzeitige oder sequentielle Hormon/Chemotherapie sowie Vergleich verschiedener Polychemotherapien in der Behandlung des metastasierenden Mammakarzinoms. Schweiz Med Wochenschr 1982;112:23–32.

    Google Scholar 

  3. Fisher B, Redmond C, Brown A et al: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;4:227–41.

    Google Scholar 

  4. Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen. Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005–18.

    PubMed  CAS  Google Scholar 

  5. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989;7:710–7.

    PubMed  CAS  Google Scholar 

  6. Pritchard KI, Paterson HG, Fine S et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:2302–11.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stuttgart

    Else Heidemann

Authors
  1. Else Heidemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heidemann, E. Kein vorteil durch zusätzliche CMF-Behandlung bei nodal positivem, postmenopausalem, Rezeptor-positivem Mammakarzinom unter adjuvanter Tamoxifen-Therapie. Strahlenther Onkol 174, 290–291 (1998). https://doi.org/10.1007/BF03038727

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03038727

Search

Navigation